Spinogenix is at the forefront of developing innovative therapeutics aimed at restoring synaptic function, which is crucial for cognitive and motor abilities. Their lead candidate, SPG302, is designed to regenerate synapses, particularly in neurodegenerative and neuropsychiatric conditions such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), schizophrenia, and Fragile X syndrome. Unlike traditional therapies that primarily focus on slowing disease progression, Spinogenix's approach seeks to reverse synaptic degeneration, thereby improving cognitive and motor functions. The company employs a proprietary technology platform known as TAGS™ (Transient Activators of Glutamatergic Synaptogenesis), which facilitates the formation of new synapses using glutamate as a neurotransmitter. This platform allows for rapid synaptic regeneration, with effects observable within weeks of treatment.

In addition to SPG302, Spinogenix is also developing SPG601, a small molecule designed to activate BK channels, which are essential for proper synaptic function. This therapy targets the underlying synaptic dysfunctions associated with Fragile X syndrome, a condition characterized by intellectual disability and autism. Spinogenix's commitment to creating patient-friendly solutions is evident in their focus on oral medications, such as once-a-day tablets, which enhance compliance and reduce treatment costs compared to existing biologic therapies that often require complex administration methods. Overall, Spinogenix's pioneering work in synaptic restoration represents a significant advancement in the treatment of various debilitating neurological conditions.

United States

Spinogenix is developing a new class of regenerative therapeutics. Spinogenix has designed SPG302, a compound that acts in an entirely new manner to help restore the brain connections (synapses) lost in neurodegenerative diseases.

Spinogenix

Company Details